Literature DB >> 26544706

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Maria Pyra1, Renee Heffron, Nelly R Mugo, Kavita Nanda, Katherine K Thomas, Connie Celum, Athena P Kourtis, Edwin Were, Helen Rees, Elizabeth Bukusi, Jared M Baeten.   

Abstract

OBJECTIVE: The objective of this study is to assess whether antiretroviral therapy (ART) may diminish the effectiveness of hormonal contraceptive methods.
METHODS: Using data from 5153 HIV-infected women followed prospectively for 1-3 years in three HIV prevention studies in Africa, we compared incident pregnancy rates by contraceptive method (implant, injectable, oral or none) and ART use. Multivariable Cox regression models were used to determine adjusted hazard ratios (aHRs) and test interactions between each method and ART use.
RESULTS: During follow-up, 9% of women ever used implants, 40% used injectables and 14% used oral contraceptives; 31% of women ever used ART, mostly nevirapine (75% of ART users) or efavirenz-based (15%). Among women not using contraception, pregnancy rates were 13.2 and 22.5 per 100 women-years for those on and not on ART, respectively. Implants greatly reduced the incidence of pregnancy among both women on ART [aHR 0.06, 95% confidence interval (95% CI) 0.01-0.45] and not on ART (aHR 0.05, 95% CI 0.02-0.11). Injectables (aHR 0.18 on ART and aHR 0.20 not on ART) and oral contraceptives (aHR 0.37 on ART and aHR 0.36 not on ART) also reduced pregnancy risk, though by lesser degrees. ART use did not significantly diminish contraceptive effectiveness, although all methods showed nonstatistically significant reduced effectiveness when concurrently using efavirenz.
CONCLUSION: Hormonal contraceptive methods are highly effective in reducing pregnancy risk in HIV-infected women, including those concurrently using ART. Studies of potential interactions between ART and contraceptives should evaluate real-world effectiveness of contraceptive methods; in this study, implants were the most effective method to prevent pregnancy, even during ART use.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26544706      PMCID: PMC4748843          DOI: 10.1097/QAD.0000000000000827

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz.

Authors:  Adetunji A Matiluko; Lakshmi Soundararjan; Patrick Hogston
Journal:  J Fam Plann Reprod Health Care       Date:  2007-10

2.  Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

Authors:  S E Cohn; J-G Park; D H Watts; A Stek; J Hitti; P A Clax; S Yu; J J L Lertora
Journal:  Clin Pharmacol Ther       Date:  2006-12-27       Impact factor: 6.875

3.  Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz.

Authors:  Nadia Leticee; Jean-Paul Viard; Amina Yamgnane; Marina Karmochkine; Alexandra Benachi
Journal:  Contraception       Date:  2011-10-27       Impact factor: 3.375

4.  Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.

Authors:  Gretchen S Stuart; Agnes Moses; Amanda Corbett; Grace Phiri; Wiza Kumwenda; Nkhafwire Mkandawire; Joseph Chintedze; Gabriel Malunga; Mina Hosseinipour; Myron S Cohen; Frank Z Stanczyk; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

5.  Implanon® failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.

Authors:  E J McCarty; H Keane; K Quinn; S Quah
Journal:  Int J STD AIDS       Date:  2011-07       Impact factor: 1.359

6.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study.

Authors:  Landon Myer; Rosalind J Carter; Monica Katyal; Patricia Toro; Wafaa M El-Sadr; Elaine J Abrams
Journal:  PLoS Med       Date:  2010-02-09       Impact factor: 11.069

8.  Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.

Authors:  Kavita Nanda; Eliana Amaral; Melissa Hays; Marco A M Viscola; Neha Mehta; Luis Bahamondes
Journal:  Fertil Steril       Date:  2007-09-19       Impact factor: 7.329

9.  Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.

Authors:  Nadia Kancheva Landolt; Nittaya Phanuphak; Sasiwimol Ubolyam; Suteeraporn Pinyakorn; Rosalin Kriengsinyot; Jennisa Ahluwalia; Parawee Thongpaeng; Meena Gorowara; Narukjaporn Thammajaruk; Surasith Chaithongwongwatthana; Joep M A Lange; Jintanat Ananworanich
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

10.  Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.

Authors:  Kimberly Scarsi; Mohammed Lamorde; Kristin Darin; Sujan Dilly Penchala; Laura Else; Shadia Nakalema; Pauline Byakika-Kibwika; Saye Khoo; Susan Cohn; Concepta Merry; David Back
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

View more
  22 in total

1.  Contraceptive Use Among HIV-Infected Females with History of Injection Drug Use in St. Petersburg, Russia.

Authors:  Brooke S West; Debbie M Cheng; Olga Toussova; Elena Blokhina; Natalia Gnatienko; Kan Liu; Jeffrey H Samet; Anita Raj
Journal:  AIDS Behav       Date:  2018-06

2.  A systematic review of contraceptive continuation among women living with HIV.

Authors:  Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones
Journal:  Contraception       Date:  2018-02-09       Impact factor: 3.375

3.  Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.

Authors:  Jennifer E Balkus; Thesla Palanee-Phillips; Krishnaveni Reddy; Samantha Siva; Ishana Harkoo; Clemensia Nakabiito; Kenneth Kintu; Gonasangrie Nair; Catherine Chappell; Flavia Matovu Kiweewa; Samuel Kabwigu; Logashvari Naidoo; Nitesha Jeenarain; Mark Marzinke; Lydia Soto-Torres; Elizabeth R Brown; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

4.  A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.

Authors:  Rena C Patel; Randy M Stalter; Katherine K Thomas; Bani Tamraz; Steven W Blue; David W Erikson; Christina J Kim; Edward J Kelly; Kavita Nanda; Athena P Kourtis; Jairam R Lingappa; Nelly Mugo; Jared M Baeten; Kimberly K Scarsi
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

5.  Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.

Authors:  Rena C Patel; Jared M Baeten; Renee Heffron; Ting Hong; Nicole L Davis; Kavita Nanda; Robert W Coombs; Jairam R Lingappa; Elizabeth A Bukusi; Stacey Hurst; Katherine K Thomas; Athena P Kourtis; Nelly Mugo
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

6.  Key influences on the decision to initiate PrEP among adolescent girls and young women within routine maternal child health and family planning clinics in Western Kenya.

Authors:  Zoe Rogers; Jillian Pintye; John Kinuthia; Gabrielle O'Malley; Felix Abuna; Jaclyn Escudero; Melissa Mugambi; Mercy Awuor; Annabell Dollah; Julia C Dettinger; Pamela Kohler; Grace John-Stewart; Kristin Beima-Sofie
Journal:  AIDS Care       Date:  2021-09-20

Review 7.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 8.  Current and future contraceptive options for women living with HIV.

Authors:  Rena C Patel; Elizabeth A Bukusi; Jared M Baeten
Journal:  Expert Opin Pharmacother       Date:  2017-09-19       Impact factor: 3.889

9.  Reduced Effectiveness of Contraceptive Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good Enough and for How Long?

Authors:  James D Shelton
Journal:  Glob Health Sci Pract       Date:  2015-12-08

10.  What's new for antiretroviral treatment in women with HIV.

Authors:  Nisha Andany; Sharon L Walmsley
Journal:  J Virus Erad       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.